GlassScriptPhysician profile
Michael Jonathan Slesinski
NPI 1104112812
$2,196.41
in general payments reported to CMS, 2019-2025
18 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $136 · 2021: $1,097 · 2023: $19.86 · 2024: $602 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $907.03 | 2021 | |
| Abbvie INC. | $275.18 | 2024-2025 | |
| Abbott Laboratories | $221.00 | 2020-2024 | Proclaim |
| Nalu Medical, INC. | $150.11 | 2024 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $125.68 | 2019 | |
| Tersera Therapeutics LLC | $119.45 | 2024-2025 | Prialt |
| Boston Scientific Corporation | $111.08 | 2020 | |
| Eisai INC. | $62.84 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $43.75 | 2024 | Dysport |
| Nevro Corp. | $33.21 | 2024 | Senza |
| Biogen, INC. | $21.55 | 2025 | Tysabri |
| Collegium Pharmaceutical, INC. | $20.39 | 2024 | Belbuca |
| International Rehabilitative Sciences, INC | $19.86 | 2023 | Rs 4i Plus Sequential Stimulator |
| Avanos Medical | $19.20 | 2024 | Generator |
| Averitas Pharma INC. | $18.96 | 2024 | Qutenza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.60 | 2025 | Keveyis |
| Biotissue Holdings INC. | $15.43 | 2024 | |
| Relievant Medsystems, INC. | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Slesinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.